The Neurodiversity Reader – Call for Submissions

News

The Neurodiversity Reader – Call for Submissions
Twenty years on – tracing the influence of the neurodiversity movement on theory and practice.

This is a call for submissions for an upcoming publication with Pavilion Press in association with PARC. Deadline for submissions of full drafts is August 30th 2019. Selected submissions will be taken forward for the published reader, whilst others will be published on the PARC website in a series of blogs (providing they do not contain material considered offensive by the editors).

Submissions should be between 1500 and 7000 words. Submissions do not have to be academic in nature and we would suggest to authors to write in an accessible style in order to be of value to a broad audience. Please send submissions to damianmilton.sociology@yahoo.com Continue reading

Advertisements

‘Inside Out’ Symposium – Call for Contributions

Events

Inside Out: autistic identities, participatory research and gender

2 day symposium: Thursday July 4 & Friday July 5 at the University of Kent

Day 1: Perspectives on participatory research practices, ethics and themes
Day 2: Perspectives on gender and creativity

Call for Contributions Continue reading

Autism Innovative Medicine Studies-2-Trials project FAQ

News

Written by: Panda Mery

As so little information has been made available on 115 million euros Autism Innovative Medicine Studies-2-Trials (AIMS-2-Trials) research project, we suggested to Autistica to publish their project agreement. They didn’t. Using the access to information scheme of the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU), we also requested a copy of the ‘Autism Innovative Medicine Studies-2 Trials (AlMS-2-Trials) grant agreement and its appendices’. After extending its deadline, the IMI2 JU sent us a partly redacted copy of the grant agreement. The redactions are explained in a cover letter. Continue reading

Attempting to lift the veil of secrecy over AIMS-2

News

Written by: Panda Mery, Dinah Murray & Kabie Brook

The Autism Innovative Medicine Studies-2-Trials (AIMS-2-Trials) was launched as the largest ever grant given to autism research on June 18th. Two weeks ago, we wrote some questions about this project and the autistic representation and monitoring, if any. Dr James Cusack, Director of Science, Autistica wrote a response that answered only some of our questions. Some people commented on both these posts (below each). Continue reading

Response from Dr. James Cusack to concerns regarding Autistica’s involvement in AIMS-2

News

Thank you to Panda, Dinah and Kabie for their post and to Damian for the opportunity to post here. It’s really good to have a nuanced discussion about Autistica’s involvement in AIMS-2-TRIALS. We are taking on board a variety of views, some critical, some undecided and some very supportive. All of these views are valid and will inform how we move forward. Continue reading